Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.

Autor: Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Döhner H; Ulm University Hospital, Ulm, Germany., Wei AH; Peter MacCallum Cancer Centre, Melbourne, Australia.; The Royal Melbourne Hospital, Melbourne, Australia., Montesinos P; Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain., Pfeilstöcker M; Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria., Papayannidis C; IRCCS, Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia 'L. e A. Seràgnoli', Bologna, Italy., Lai Y; Bristol Myers Squibb, Princeton, New Jersey, USA., Wang K; Bristol Myers Squibb, Princeton, New Jersey, USA., See WL; Bristol Myers Squibb, San Francisco, California, USA., de Menezes DL; Bristol Myers Squibb, San Francisco, California, USA., Petrlik E; Bristol Myers Squibb, Princeton, New Jersey, USA., Prebet T; Bristol Myers Squibb, Summit, New Jersey, USA., Roboz GJ; Weill Cornell Medicine, New York, New York, USA.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Mar; Vol. 204 (3), pp. 877-886. Date of Electronic Publication: 2023 Nov 12.
DOI: 10.1111/bjh.19202
Abstrakt: In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for haematopoietic stem cell transplant (HSCT), oral azacitidine (Oral-AZA) maintenance significantly prolonged overall survival (OS) versus placebo. The impact of subsequent treatment following maintenance has not been evaluated. In this post hoc analysis, OS was estimated for patients who received subsequent AML therapy, and by regimen received (IC or lower-intensity therapy). First subsequent therapy (FST) was administered after treatment discontinuation in 134/238 Oral-AZA and 173/234 placebo patients. OS from randomization in patients who received FST after Oral-AZA versus placebo was 17.8 versus 12.9 months (HR: 0.82 [95% CI: 0.64-1.04], median follow-up: 56.7 months); OS from FST was similar between arms. Among patients who received injectable hypomethylating agents as FST, median OS was 8.2 versus 4.9 months in the Oral-AZA versus placebo groups (HR: 0.66 [95% CI: 0.41-1.06]). Forty-eight patients (16/238 Oral-AZA, 32/234 placebo) received HSCT following treatment discontinuation, including six Oral-AZA patients still in first remission; Oral-AZA OS benefit persisted when censoring these patients. Oral-AZA maintenance can prolong AML remission duration without negatively impacting survival outcomes after salvage therapies.
(© 2023 Bristol Myers Squibb and The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: